We are committed to innovation and constantly pushing the boundaries of science
MedImmune employees globally
Biologics in research and development
Publications in 2014
Our team of world-renowned scientists collaborate to support the identification and validation of targets regulating biological processes which are the fundamental drivers of human disease. Using a variety of tools, including in vivo and in vitro assays and bio-informatic approaches, our scientists rigorously test biological hypotheses across our focus areas.
Our Antibody Discovery and Protein Engineering Department applies cutting-edge technologies in the discovery of novel therapeutic biologics to change the lives of patients. The team works collaboratively across all focus areas and deploy a plethora of innovative in-house platform technologies such as phage and ribosome display, Fc engineering, and novel peptide discovery methodologies. We have an exceptional track record of delivery having discovered and engineered approaching 100 protein therapeutics that have entered the clinic.
Our translational expertise enables us to accelerate drug development in human disease by selecting the right patients in early clinical trials. We accomplish this by embedding human target validation earlier in research, utilising innovative clinical trial design approaches and integrating multiple, relevant scientific insights across our focus areas.
As a leader in personalised healthcare, we are committed to matching new medicines to the patients most likely to benefit. We combine industry-leading expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers, and we work collaboratively with our external partners to harness breakthrough technologies across the life-cycle of our medicines.
Early clinical development
Our Early Clinical Development team specialises in the integration of quantitative data analysis developed using the latest model-based drug development techniques and technologies. This insight enables our project teams to make quicker, more robust decisions throughout the R&D life-cycle of our medicines.
Our Biopharmaceutical Development team develops the process and analytics to produce and characterise product candidates, including the formulations and drug product forms, for delivering medicines to patients. Working closely with research, the team helps define and select the best product candidates to progress into development.
Personalised medicine at MedImmune
"We overcame the challenges and put the antibody to the test in human clinical trials and it worked perfectly. It's like a Eureka! moment. Not many people can have that type of experience."
Fostering scientific creativity
Committed to driving innovation, no matter where it hides
Commitment to science
Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study
Published: 17 August 2017
AstraZeneca/MedImmune author: Joyce Antal, Xiaoping Jin, Ashok Gupta
In silico design of context-responsive mammalian promoters with user-defined functionality
Published: 30 August 2017
Area: R&D (Early Development)
AstraZeneca/MedImmune author: Suzanne Gibson, Diane Hatton
Fractionated dosing improves preclinical therapeutic index of pyrrolobenzodiazepine-containing antibody drug conjugates
Published: 23 August 2017
AstraZeneca/MedImmune author: Mary Jane Masson Hinrichs, Pauline Ryan, Bo Zheng
Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Published: 10 August 2017
AstraZeneca/MedImmune author: Sarah Will, David Hornigold, David Baker
Role of CD11c+ T-bet+ B cells in human health and disease
Published: 11 June 2017
AstraZeneca/MedImmune author: Jodi Karnell, Varsha Kumar, Jingya Wang, Shu Wang, Elisaveta Voynova, Rachel Ettinger
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
Published: 03 August 2017
AstraZeneca/MedImmune author: Keith Steele
High-throughput quantitation of Fc-containing recombinant proteins in cell culture supernatant by fluorescence polarization spectroscopy
Published: 01 October 2017
Area: R&D (Early Development)
AstraZeneca/MedImmune author: Mike Jenns
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers
Published: 22 August 2017
AstraZeneca/MedImmune author: Raburn Mallory
Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy
Published: 20 May 2015
Area: Inflammation and Autoimmunity
AstraZeneca/MedImmune author: Tomas Mustelin
IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk
Published: 16 March 2015
AstraZeneca/MedImmune author: Richard May (MedImmune)
Low-frequency coding variants at 6p22.2-6p21.31 and 20q11.21 are associated with lung cancer risk in Chinese populations
Published: 7 May 2015
AstraZeneca/MedImmune author: Brandon Higgs
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.